The approval applies to the treatment of adult patients with mild dementia or mild cognitive impairment due to Alzheimer's disease.
The drug Leqembi has been developed through a collaboration between Swedish Bioarctic and Japanese Eisai. Eisai is responsible for the clinical development and global sales.
